SK Biopharmaceuticals Co. Ltd. has signed a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire rights to WARF’s WT-7695, a preclinical-stage radiopharmaceutical therapy candidate developed in collaboration with the University of Wisconsin-Madison.
South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.
South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.
A team of scientists from KTH Royal Institute of Technology and Karolinska Institutet has reported the development and characterization of a new class of small non-immunoglobulin affibody proteins that bind to the highly glycosylated human carcinoembryonic antigen-related adhesion molecule 5 (CEACAM5, CEA) with high affinity.
Simon Fraser University, TRIUMF and the University of British Columbia have disclosed radiolabeled compounds reported to be useful for the diagnosis of cancer.
A team of U.S. and South Korean researchers have developed an AI model called MSI-SEER that can not only predict microsatellite instability-high (MSI-H) tumors based on tissue slides, but also flag “what it does not know.” “Have you ever asked ChatGPT anything, and the response was, ‘I don’t know?’” Cheong Jae-ho asked during an interview with BioWorld. “Probably not, and that is the problem with AI now.”
Nanjing Nuoyuan Medical Devices Co. Ltd. has discovered drug conjugates comprising a fluorescent moiety targeting hepatocyte growth factor receptors (HGFR; MET) covalently linked to crizotinib through a linker. They are reported to be useful for diagnosis of liver and colon cancer.
IMU Biosciences Ltd. is working to transform society’s understanding of the immune system. The company’s platform maps the immune system at molecular, cellular and system levels, to unlock new insights into immune-related health and diseases, paving the way for clinical applications that could improve patient outcomes.
RSS
